174 related articles for article (PubMed ID: 8701398)
1. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
[TBL] [Abstract][Full Text] [Related]
2. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of prothrombin fragment 1+2, thrombin antithrombin III complexes and D-dimer measurements in the diagnosis of deep vein thrombosis following total hip replacement.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1998 Mar; 79(3):509-10. PubMed ID: 9531030
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
[TBL] [Abstract][Full Text] [Related]
6. Coagulation activation markers in the prediction of venous thrombosis after elective hip surgery.
Cofrancesco E; Cortellaro M; Corradi A; Ravasi F; Bertocchi F
Thromb Haemost; 1997 Feb; 77(2):267-9. PubMed ID: 9157579
[TBL] [Abstract][Full Text] [Related]
7. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
[TBL] [Abstract][Full Text] [Related]
9. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group.
Schiele F; Lindgaerde F; Eriksson H; Bassand JP; Wallmark A; Hansson PO; Grollier G; Sjo M; Moia M; Camez A; Smyth V; Walker M
Thromb Haemost; 1997 May; 77(5):834-8. PubMed ID: 9184388
[TBL] [Abstract][Full Text] [Related]
11. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
12. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty.
van den Bos AA; Deckers JW; Heyndrickx GR; Laarman GJ; Suryapranata H; Zijlstra F; Close P; Rijnierse JJ; Buller HR; Serruys PW
Circulation; 1993 Nov; 88(5 Pt 1):2058-66. PubMed ID: 8222099
[TBL] [Abstract][Full Text] [Related]
14. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. European Hirudin in Thrombosis Group.
Verstraete M; Nurmohamed M; Kienast J; Siebeck M; Silling-Engelhardt G; Büller H; Hoet B; Bichler J; Close P
J Am Coll Cardiol; 1993 Oct; 22(4):1080-8. PubMed ID: 8409044
[TBL] [Abstract][Full Text] [Related]
15. Recombinant hirudin as a periprocedural antithrombotic in coronary angioplasty for unstable angina pectoris.
Hafner G; Rupprecht HJ; Luz M; Terres W; Schindel F; Friesen HJ; Heinrichs H; Jessel A; Meyer J; Prellwitz W
Eur Heart J; 1996 Aug; 17(8):1207-15. PubMed ID: 8869862
[TBL] [Abstract][Full Text] [Related]
16. The comparative effects of recombinant hirudin (CGP 39393) and standard heparin on thrombus growth in rabbits.
Agnelli G; Pascucci C; Cosmi B; Nenci GG
Thromb Haemost; 1990 Apr; 63(2):204-7. PubMed ID: 2363121
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of selected parameters of blood coagulation and the fibrinolysis system in patients undergoing total hip replacement].
Sokołowska B; Piecuch W; Walter-Croneck A; Dmoszyńska A; Furmanik F
Przegl Lek; 2002; 59(7):502-8. PubMed ID: 12516238
[TBL] [Abstract][Full Text] [Related]
18. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery.
Agnelli G; Sonaglia F
Semin Thromb Hemost; 1997; 23(2):143-8. PubMed ID: 9200338
[TBL] [Abstract][Full Text] [Related]
19. Distinct effects of recombinant desulfatohirudin (Revasc) and heparin on plasma levels of fibrinopeptide A and prothrombin fragment F1.2 in unstable angina. A multicenter trial.
Rao AK; Sun L; Chesebro JH; Fuster V; Harrington RA; Schwartz D; Gallo P; Matos D; Topol EJ
Circulation; 1996 Nov; 94(10):2389-95. PubMed ID: 8921778
[TBL] [Abstract][Full Text] [Related]
20. Experimental studies on a recombinant hirudin, CGP 39393.
Gray E; Watton J; Cesmeli S; Barrowcliffe TW; Thomas DP
Thromb Haemost; 1991 Apr; 65(4):355-9. PubMed ID: 2057916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
